Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
The Journal of Family Practice|July 1, 2022
Current Challenges in the Management of Skin and Soft Tissue Infections and Community-Acquired PneumoniaMelanie Lauterio, Daniel H Deck
Expert Review of Anti-Infective Therapy|January 31, 2006
Pharmacological advances in the treatment of invasive candidiasisDaniel H Deck, B Joseph Guglielmo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2012
Does doxycycline protect against development of Clostridium difficile infection?Sarah B Doernberg, Lisa G Winston, Daniel H Deck, et al.
Infectious Diseases and Therapy|July 3, 2016
Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management SettingDaniel H Deck, Jennifer M Jordan, Thomas L Holland, et al.
Open Forum Infectious Diseases|June 23, 2021
Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC StudyJulio Ramirez, Daniel H Deck, Paul B Eckburg, et al.
Msphere|July 9, 2024
Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of M. abscessus lung diseaseElisa H Ignatius, Binayak Rimal, Chandra M Panthi, et al.
Tuberculosis (Edinburgh, Scotland)|February 16, 2024
Efficacies of three drug regimens containing omadacycline to treat Mycobacteroides abscessus diseaseBinayak Rimal, Chandra M Panthi, Yi Xie, et al.
Msphere|March 13, 2023
Efficacy of Omadacycline-Containing Regimen in a Mouse Model of Pulmonary Mycobacteroides abscessus DiseaseBinayak Rimal, Danielle A Nicklas, Chandra M Panthi, et al.
Military Medicine|November 14, 2023
A Review of Omadacycline for Potential Utility in the Military Health System for the Treatment of Wound InfectionsDaniel V Zurawski, Alisa W Serio, Chad Black, et al.
Eclinicalmedicine|December 4, 2025
Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trialThomas M File, Keith S Kaye, Skliarov Ihor, et al.
Pageof 2